Abstracts tagged "osteoporosis"

Abstract Number: 1304 • ACR Convergence 2022
Glucocorticoids Affect Bone Mass and Strength by Inhibiting Osteoprogenitor Cell Maturation
Thomas Ambrosi¹, Mathew Murphy¹, Charles KF Chan¹ and Nancy Lane², ¹Stanford University, Stanford, CA, ²University of California Davis, Hillsborough, CA
Background/Purpose: Glucocorticoid (GC) induced osteoporosis remains a significant health issue. While GCs are known to reduce bone formation and bone mass, patients treated with GCs…
Abstract Number: 1323 • ACR Convergence 2022
Secondary Prevention of Vertebral Fractures Sustained Efficacy over Time
JOSE ELOY OLLER RODRIGUEZ¹, Elena Grau García², Samuel Leal Rodriguez³, Laura Mas Sanchez², Pablo Francisco Muñoz Martínez⁴, Carmen Riesco Bárcena⁵, Anderson Huaylla Quispe⁶, Cristobal Pavez Perales², Francisco Miguel Ortiz Sanjuan⁷, José Ivorra Cortés², Inés Cánovas Olmos², Luis González Puig⁸, Isabel Martínez-Cordellat², Carmen Nájera Herranz⁷, Rosa Negueroles Albuixech², Elvira Vicens Bernabeu⁷, Alba Torrat Novés⁵, Daniel Ramos Castro² and José andrés Román ivorra³, ¹Hospital Universitario de La Fe, València, Spain, ²Rheumatology Department. Hospital Universitario y Politécnico La Fe, València, Spain, ³Hospital Universitari i Politécnic La Fe, València, Spain, ⁴Hospital Universitario y Politécnico La Fe, València, Spain, ⁵Rheumatology Department. Hospital Universitario y Politécnico La Fe, València, ⁶Medicina, València, Spain, ⁷Hospital Universitario de La Fe, València, ⁸Rheumatology Department. Hospital Universitario y Politécnico La Fe, Torrente, Valencia, Spain
Background/Purpose: Vertebral fractures entail a notorious social and health problem, and their presence is the greatest risk factor for the appearance of a new vertebral…
Abstract Number: 1305 • ACR Convergence 2022
Characterizing Bone Microarchitecture with MRI in Patients with Systemic Lupus Erythematosus
Joshua Novack¹, Gregory Chang², Stephen Honig¹, Anmol Monga², Xiaoliu Zhang³, Punam Saha³, Dimitri Martel², Peter Izmirly⁴, H Michael Belmont⁵, Jill Buyon⁴ and Amit Saxena⁵, ¹NYU Langone Health Department of Medicine, New York, NY, ²NYU Langone Health Department of Radiology, New York, NY, ³University of Iowa Departments of Radiology and Electrical and Computer Engineering, Iowa City, IA, ⁴NYU Grossman School of Medicine, New York, NY, ⁵NYU School of Medicine, New York, NY
Background/Purpose: Fractures in patients with systemic lupus erythematosus (SLE) are more common than age and sex matched controls. Fracture risk is traditionally assessed by dual-energy…
Abstract Number: 1325 • ACR Convergence 2022
The Risks of Osteoporotic Fracture After Lung Transplant: A Retrospective Cohort Study at an International Transplant Center
Adil Vural¹, Sarah Keller², Neel Tapryal³, Komal Mushtaq⁴, Hassan Shaheen¹, Chao Zhang², Marie Budev², Abby Abelson² and Chad Deal⁵, ¹Cleveland Clinic, Westlake, OH, ²Cleveland Clinic, Cleveland, OH, ³Cleveland Clinic, Rocky River, OH, ⁴Cleveland Clinic, Fairview Park, OH, ⁵Cleveland Clinic, Shaker Heights, OH
Background/Purpose: Osteoporotic fractures are a well-known complication of lung transplant (LT) and can significantly impact the quality of life of LT recipients. Although much is…
Abstract Number: 1306 • ACR Convergence 2022
Improving Osteoporosis Screening in Individuals of Color
Megan Brochu¹, Kristofer Marcus¹, Sarah Latorre¹, Francis Wanjau¹, Arvin Garg², Eric Alper², Rulan Lyu¹, Tracey Wilkie¹ and Jonathan Cheah³, ¹UMass Memorial Health, Worcester, MA, ²UMass Memorial Health, UMass Chan Medical School, Worcester, MA, ³UMass Chan Medical School, Worcester, MA
Background/Purpose: Osteoporosis, including the clinical event of fragility fracture is an ever-increasing public health burden. Effective screening techniques and well as therapies to reduce future…
Abstract Number: 1326 • ACR Convergence 2022
Impact of COVID-19 Severity on Bone Mineral Density, Sarcopenia and Physical Performance Among Older Adults Following Hospitalization: A Pilot Study
Diego Cabrera¹, Clara Wong², Andrew Cohen³, Lauren Ferrante³, Alexandra Hajduk³ and Evelyn Hsieh¹, ¹Section of Rheumatology, Allergy and Immunology, Yale School of Medicine, New Haven, CT, ²Yale School of Public Health, New Haven, CT, ³Yale School of Medicine, New Haven, CT
Background/Purpose: Altered bone mineral density (BMD), muscle mass and physical performance has been associated with adverse outcomes, however, the effect of COVID-19 on the musculoskeletal…
Abstract Number: 1307 • ACR Convergence 2022
Effect of Romosozumab in Postmenopausal Women with Knee Osteoarthritis: Results from the FRAME Clinical Trial
Nancy Lane¹, Donald Betah², Cynthia Deignan², Mary Oates², Zhenxun Wang², Jen Timoshenko³, Aliya Khan⁴ and Neil Binkley⁵, ¹University of California Davis, Hillsborough, CA, ²Amgen, Inc., Thousand Oaks, CA, ³UCB Pharma, Slough, United Kingdom, ⁴McMaster University, Oakville, ON, Canada, ⁵University of Wisconsin, Madison, WI
Background/Purpose: Osteoarthritis (OA) and osteoporosis (OP) often occur concomitantly in the elderly. The relationship between OA and OP is complex, with increased fracture risk reported…
Abstract Number: 1327 • ACR Convergence 2022
Immune Cell Subsets and Risk of Incident Hip Fracture in Older Adults: The Cardiovascular Health Study
Rachel Elam¹, Petra Buzkova², Joseph Delaney³, Howard Fink⁴, Joshua Barzilay⁵, Laura Carbone¹, Rick Saha¹, John Robbins⁶, Kenneth Mukamal⁷, Rodrigo Valderrabano⁸, Bruce Psaty², Russell Tracy⁹, Nels Olson⁹, Sally Huber¹⁰, Margaret Doyle⁹, Alan Landay¹¹ and Jane Cauley¹², ¹Augusta University, Augusta, GA, ²University of Washington, Seattle, WA, ³University of Manitoba, Winnipeg, MB, Canada, ⁴University of Minnesota, Minneapolis, MN, ⁵Kaiser Permanente, Atlanta, GA, ⁶UC Davis, Davis, CA, ⁷Beth Israel Deaconess Medical Center, Boston, MA, ⁸Brigham and Women's Hospital, Boston, MA, ⁹University of Vermont, Burlington, VT, ¹⁰University of Vermont, Burlingon, VT, ¹¹Rush University Medical Center, Chicago, IL, ¹²University of Pittsburgh, PIttsburgh, PA
Background/Purpose: Cell-mediated immunity may play a role in osteoporosis development. Fracture is the major consequence of osteoporosis. Thus, cell-mediated immunity may impact fracture risk. We…
Abstract Number: 1308 • ACR Convergence 2022
Prevalence and Therapeutic Practices of Osteoporosis in Sarcoidosis in the United States: A Nationwide Registry Study
Diala Alawneh¹, Moustafa Younis², Romesa Hassan¹, Bashar Alzghoul², Shiva Arami¹, Tricha Shivas³, Mary McGowan³, Khaldoon Alawneh⁴, Christian Ascoli¹ and Nadera Sweiss¹, ¹University of Illinois at Chicago, Chicago, IL, ²University of Florida, Gainesville, FL, ³Foundation for Sarcoidosis Research, Chicago, IL, ⁴Jordan University of Science and Technology, Irbid, Jordan
Background/Purpose: Patients with sarcoidosis are at an increased risk of developing osteoporosis due to the active inflammatory state and chronic corticosteroid use. Proper dosing of…
Abstract Number: 1328 • ACR Convergence 2022
CT Evaluation of Bone Fragility 2 Years After Bariatric Surgery in Patients with Obesity: An Observational Study
Marine FAUNY¹, Marion Halin², Edem Allado², Didier Quilliot², Laurent Brunaud², Eliane Albuisson², Isabelle Chary-Valckenaere² and Damien Loeuille², ¹Nancy University Hospital, Toul, France, ²Nancy University Hospital, Vandoeuvre, France
Background/Purpose: The objectives were to evaluate bone fragility on computed tomography (CT) in patients with obesity before and 2 years after bariatric surgery and to…
Abstract Number: 0262 • ACR Convergence 2022
Predictors of Fragility Fracture Amongst Patients with Rheumatoid Arthritis: An Observational Cohort Study
Seema Sharma¹ and Marwan Bukhari², ¹Lancaster Royal Infirmary, Lancaster, United Kingdom, ²University Hospitals of Morecambe Bay NHS Trust, Lancaster, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) is associated with reduced bone mineral density and almost one third of this population have osteoporosis leading to increased risk of…
Abstract Number: 1309 • ACR Convergence 2022
Evaluation of Preference and Efficacy in the Treatment of Glucocorticoid-induced Osteoporosis in Patients with Autoimmune Diseases Receiving Zoledronic Acid
Ji-Won Kim¹, Ju-Yang Jung¹, Hyoun-Ah Kim¹ and Chang-Hee Suh², ¹Ajou University School of Medicine, Suwon, Republic of Korea, ²Ajou University Hospital, Suwon, Republic of Korea
Background/Purpose: The most commonly used drugs for glucocorticoid-induced osteoporosis (GIOP) is bisphosphonates, which include oral alendronate and risedronate, and intravenous zoledronic acid. Among them, zoledronic…
Abstract Number: 1329 • ACR Convergence 2022
Prevalence of Bone Fragility on DXA and CT in Patients with Obesity
Marion Halin¹, Edem Allado¹, Didier Quilliot¹, Eliane Albuisson¹, Isabelle Chary-Valckenaere¹, Damien Loeuille¹, Laurent Brunaud¹ and Marine FAUNY², ¹Nancy University Hospital, Vandoeuvre, France, ²Nancy University Hospital, Toul, France
Background/Purpose: Primary objective was to evaluate bone fragility prevalence on dual X-ray absorptiometry (DXA) and on computed tomography (CT), in patients with severe obesity. Secondary…
Abstract Number: 0446 • ACR Convergence 2021
Clinical Characteristics, Including History of Myocardial Infarction and Stroke, Among US PMO Women Initiating Treatment with Romosozumab and Other Anti-osteoporosis Therapies
Jay Lin¹, Carrie Nielson¹, Mary Oates¹, Cynthia Deignan² and Zhigang Yu¹, ¹Amgen Inc., Thousand Oaks, CA, ²Amgen, Inc., Agoura Hills, CA
Background/Purpose: This study is an ongoing USFDA post-marketing requirement (2020-2024) to assess the impact of boxed warning on romosozumab (romo) treatment and the feasibility of…
Abstract Number: 0447 • ACR Convergence 2021
Bone Anabolic Effects of a Novel Orally-Available Small Molecule SIK2/SIK3 Inhibitor
Cheng-Chia Tang¹, Shiv Verma¹, Steve De Vos², David Amantini³, Philippe Clement-Lacroix³, Nicolas Desroy³, Antonio Speziale⁴, Daniel Brooks⁵, Mary Bouxsein⁵, Janaina da Silva Martins¹, Yingshe Zhao⁶, Henry Kronenberg¹ and Marc Wein¹, ¹MGH Endocrine Unit, Boston, MA, ²Galapagos NV, Mechelen, Belgium, ³Galapagos SASU, Romainville, France, ⁴Galapagos GmbH, Basel, Switzerland, ⁵Beth Israel Deaconess Medical Center, Boston, MA, ⁶MGH Endocrine Unnit, Boston, MA
Background/Purpose: Orally-available bone anabolic agents represent a major unmet medical need for patients with osteoporosis. Widespread use of parathyroid hormone (PTH)-based osteo-anabolic therapies is limited…

« Previous Page
1
…
7
8
9
10
11
…
20
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].